Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL23629791 | 0.87 | MKNK1 (0.41) | PARP1CYP3A4CYP2C19MKNK1MAP4K4 | |
| Adenine SCHEMBL15699 | 0.85 | F7 (0.56) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL22748483 | 0.85 | F7 (0.56) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL2564207 | 0.85 | F7 (0.56) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL8414752 | 0.85 | F7 (0.52) | PARP1MKNK1EGFRROCK2PIM1 | |
| Adenine SCHEMBL9621204 | 0.84 | GDA (0.46) | PARP1MKNK1MAP4K4GSK3BGDA | |
| Adenine SCHEMBL23859925 | 0.84 | F7 (0.55) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL22129922 | 0.84 | F7 (0.55) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL23531099 | 0.84 | F7 (0.55) | PARP1MKNK1EGFRPIM1CDK2 | |
| Adenine SCHEMBL7712105 | 0.84 | F7 (0.55) | PARP1POLBMKNK1EGFRPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | UNIV OREGON HEALTH & SCIENCE (US) | 2023-07-06 | — | — | US | claimed |
| WO-2021262548-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-12-30 | — | — | WO | claimed |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | claimed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | claimed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | claimed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | claimed |
| EP-4370125-A1 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | Oregon Health and Science University (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024013349-A1 | BENZAMIDE ADENINE DINUCLEOSIDE COMPOUNDS AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013349-A1 | BENZAMIDE ADENINE DINUCLEOSIDE COMPOUNDS AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-01-18 | — | — | WO | disclosed |
| US-11834470-B2 | 4-thioribose NAD analogues and methods of synthesizing and using the same | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | UNIV OREGON HEALTH & SCIENCE (US) | 2023-07-06 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2023288002-A1 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | disclosed |
| EP-1349562-A2 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY | Duke University (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030148966-A1 | Method and composition for inducing apoptosis in cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE OF INDIANA UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| US-20020128205-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY OFFICE OF SCIENCE AND TECHNOLOGY (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002055018-A2 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY | DUKE UNIVERSITY (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
| US-5902792-A | Method of inducing apoptosis in cancer cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1999-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834470-B2 | 4-thioribose NAD analogues and methods of synthesizing and using the same | CD38, NQO1, NADK | PARP1 95/4885POLB 1634/4885CYP3A4 395/4885 |
| US-20020128205-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | GGH, GSS, GSR | PARP1 1941/4885POLB 1568/4885CYP3A4 731/4885 |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | SARM1, PARP16, NAMPT | PARP1 40/4885POLB 2017/4885CYP3A4 4150/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | PARP1 62/4885POLB 3419/4885CYP3A4 4586/4885 |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | PARP1 2737/4885POLB 2211/4885CYP3A4 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.